# Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled

Study · id `cardio:ct-nct01699932` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01699932](<https://clinicaltrials.gov/study/NCT01699932>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01699932

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 167 participants.

## Technical summary

Registry record NCT01699932. Non-randomized; no masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 167 participants (enrolled count; ClinicalTrials.gov record NCT01699932, source copy `cardio:ctgov-nct01699932-2014-05-08`, retrieved 2026-10-26)
- Start date: 2012-09 (registry gives no type) (ClinicalTrials.gov record NCT01699932, source copy `cardio:ctgov-nct01699932-2014-05-08`, retrieved 2026-10-26)
- Primary completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01699932, source copy `cardio:ctgov-nct01699932-2014-05-08`, retrieved 2026-10-26)
- Completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01699932, source copy `cardio:ctgov-nct01699932-2014-05-08`, retrieved 2026-10-26)
- Countries: Lebanon; Russia; Ukraine (ClinicalTrials.gov record NCT01699932, source copy `cardio:ctgov-nct01699932-2014-05-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01699932-2014-05-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled
- Acronym: LEGEND
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Glimepiride+metformin (Amaryl M®) - HOE4900
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 44cc19a427e8f591557d122c47277db225454ed7698e84f8355382595875c14e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
